Home 1

Patient Testimonials

Hear from our patients and their experiences with Longoria Cardiovascular

Innovative Care

Cutting edge techniques and minimally invasive procedures to improve outcome and patient care.

Restoring Confidence

Cardiac surgery can be an overwhelming process and we are here to guide you and your family on what to expect before, during and after your procedure.

Serving Northern California

Experience cardiac care with nationally recognized outcomes at a local level. Dr. Longoria understands that being diagnosed with any cardiac condition can be overwhelming for patients and families. His goals are to alleviate you and your families concerns and guide you through the process. From structural heart interventions to complex cardio-thoracic procedures, Dr. Longoria offers world-class cardiac care to return to you to your optimal health.

Common Procedures Performed

Best Cardiac Surgeon Pleasanton - Dr. James Longoria

25 +

Years Of Experience

Our Experience

Powered by thousands of patients that trust us with their health.




Mitral Valve Repairs


Thoracoscopic Mazes


Aortic Valves

Inventor of TT Maze Procedure

Patent Holder

Recent Articles and News

Dr. Longoria believes in keeping up with current standards of practice and further applying those standards to his patients. He continues to practice in this manner and believes in a comprehensive approach to your health with goal directed objectives. Whether it is a novel technique or an established procedure; the choices are available for you.

BMJ Heart

  • Association of household income and adverse outcomes in patients with atrial fibrillation
    by LaRosa, A. R., Claxton, J., O'Neal, W. T., Lutsey, P. L., Chen, L. Y., Bengtson, L., Chamberlain, A. M., Alonso, A., Magnani, J. W. on October 12, 2020 at 8:00 am

    BackgroundSocial determinants of health are relevant to cardiovascular outcomes but have had limited examination in atrial fibrillation (AF). ObjectivesThe purpose of this study was to examine the association of annual household income and cardiovascular outcomes in individuals with AF. MethodsWe analysed administrative claims for individuals with AF from 2009 to 2015 captured by a health claims database. We categorised estimates of annual household income as <$40 000; $40–$59 999; $60–$74 999; $75–$99 999; and ≥$100 000. Covariates included demographics, education, cardiovascular disease risk factors, comorbid conditions and anticoagulation. We examined event rates by income category and in multivariable-adjusted models in reference to the highest income category (≥$100 000). ResultsOur analysis included 336 736 individuals (age 72.7±11.9 years; 44.5% women; 82.6% white, 8.4% black, 7.0% Hispanic and 2.1% Asian) with AF followed for median (25th and 75th percentile) of 1.5 (95% CI 0.6 to 3.0) years. We observed an inverse association between income and heart failure and myocardial infarction (MI) with evidence of progressive risk across decreased income categories. Individuals with household income <$40 000 had the greatest risk for heart failure (HR 1.17; 95% CI 1.05 to 1.30) and MI (HR 1.18; 95% CI 0.98 to 1.41) compared with those with income ≥$100 000. ConclusionsWe identified an association between lower household income and adverse outcomes in a large cohort of individuals with AF. Our findings support consideration of income in the evaluation of cardiovascular risk in individuals with AF.

  • Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease
    by Hageman, S. H. J., de Borst, G. J., Dorresteijn, J. A. N., Bots, M. L., Westerink, J., Asselbergs, F. W., Visseren, F. L. J., on behalf of the UCC-SMART Study Group, Asselbergs, Nathoe, de Borst, Bots, Geerlings, Emmelot, de Jong, Leiner, Lely, van der Kaaij, Kappelle, Ruigrok, Verhaar, Visseren, Westerink on October 12, 2020 at 8:00 am

    AimTo determine the relationship between non-high-density lipoprotein cholesterol (non-HDL-c), systolic blood pressure (SBP) and smoking and the risk of major adverse limb events (MALE) and the combination with major adverse cardiovascular events (MALE/MACE) in patients with symptomatic vascular disease. MethodsPatients with symptomatic vascular disease from the Utrecht Cardiovascular Cohort - Secondary Manifestations of ARTerial disease (1996–2017) study were included. The effects of non-HDL-c, SBP and smoking on the risk of MALE were analysed with Cox proportional hazard models stratified for presence of peripheral artery disease (PAD). MALE was defined as major amputation, peripheral revascularisation or thrombolysis in the lower limb. ResultsIn 8139 patients (median follow-up 7.8 years, IQR 4.0–11.8), 577 MALE (8.7 per 1000 person-years) and 1933 MALE/MACE were observed (29.1 per 1000 person-years). In patients with PAD there was no relation between non-HDL-c and MALE, and in patients with coronary artery disease (CAD), cerebrovascular disease (CVD) or abdominal aortic aneurysm (AAA) the risk of MALE was higher per 1 mmol/L non-HDL-c (HR 1.14, 95% CI 1.01 to 1.29). Per 10 mm Hg SBP, the risk of MALE was higher in patients with PAD (HR 1.06, 95% CI 1.01 to 1.12) and in patients with CVD/CAD/AAA (HR 1.15, 95% CI 1.08 to 1.22). The risk of MALE was higher in smokers with PAD (HR 1.45, 95% CI 0.97 to 2.14) and CAD/CVD/AAA (HR 7.08, 95% CI 3.99 to 12.57). ConclusionsThe risk of MALE and MALE/MACE in patients with symptomatic vascular disease differs according to vascular disease location and is associated with non-HDL-c, SBP and smoking. These findings confirm the importance of MALE as an outcome and underline the importance of risk factor management in patients with vascular disease.

  • Association between right ventricle dysfunction and poor outcome in patients with septic shock
    by Kim, J.-s., Kim, Y.-J., Kim, M., Ryoo, S. M., Kim, W. Y. on October 12, 2020 at 8:00 am

    ObjectiveSepsis-induced myocardial dysfunction (SIMD) can involve both the left and right ventricles. However, the characteristics and outcomes across various manifestations of SIMD remain unknown. MethodsThis was a retrospective cohort study using a prospective registry of septic shock from January 2011 and April 2017. Patients with clinically presumed cardiac dysfunction underwent echocardiography within 72 hours after admission and were enrolled (n=778). SIMD was classified as left ventricle (LV) systolic/diastolic and right ventricle (RV) dysfunction, which were defined based on the American Society of Echocardiography criteria. The primary outcome was 28-day mortality. ResultsOf the 778 septic shock patients who underwent echocardiography, 270 (34.7%) showed SIMD. The median age was 67.0 years old, and the male was predominant (57.3%). Among them, 67.3% had LV systolic dysfunction, 40.7% had RV dysfunction and 39.3% had LV diastolic dysfunction. Although serum lactate level and sequential organ failure assessment score were not significantly different between groups, SIMD group showed higher troponin I (0.1 vs 0.1 ng/mL; p=0.02) and poor clinical outcomes, including higher 28-day mortality (35.9 vs 26.8%; p<0.01), longer intensive care unit length of stay (5 vs 2 days; p<0.01) and prolonged mechanical ventilation (9 vs 4 days; p<0.01). Multivariate analysis showed that isolated RV dysfunction was an independent risk factor of 28-day mortality (OR 2.26, 95% CI 1.04 to 4.91). ConclusionsOne-third of patients with septic shock showed various myocardial dysfunctions. LV systolic dysfunction was common; however, only RV dysfunction was associated with short-term mortality.

Web MD

  • Virologists: What Do They Do?
    on October 20, 2020 at 5:46 pm

    Virologists are highly skilled medical experts who manage the diagnosis, treatment, and prevention of infectious diseases such as hepatitis C, Ebola, and now COVID-19. Learn more about them.

  • Microplastics Seeping Out of Baby Bottles: Study
    on October 20, 2020 at 4:03 pm

    Infants are likely exposed to an average daily dose of nearly 1.6 million microplastic particles through baby formula they drink from heated plastic bottles, researchers estimated in the Oct. 19 issue of Nature.

  • New Rheumatoid Arthritis Drug May Help Tough Cases
    on October 19, 2020 at 8:48 pm

    The drug, marketed under the brand name Rinvoq, also helped twice as many patients enter remission from their rheumatoid arthritis, according to a report in the Oct. 15 issue of the New England Journal of Medicine.